- Home
- LPTX vs UEIC Comparison
LPTX vs UEIC Comparison
Compare LPTX & UEIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- UEIC
- Stock Information
- Founded
- LPTX 2011
- UEIC 1986
- Country
- LPTX United States
- UEIC United States
- Employees
- LPTX N/A
- UEIC N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- UEIC Consumer Electronics/Appliances
- Sector
- LPTX Health Care
- UEIC Consumer Staples
- Exchange
- LPTX Nasdaq
- UEIC Nasdaq
- Market Cap
- LPTX 117.1M
- UEIC 103.5M
- IPO Year
- LPTX N/A
- UEIC 1993
- Fundamental
- Price
- LPTX $2.74
- UEIC $10.95
- Analyst Decision
- LPTX Strong Buy
- UEIC Strong Buy
- Analyst Count
- LPTX 4
- UEIC 2
- Target Price
- LPTX $8.63
- UEIC $14.50
- AVG Volume (30 Days)
- LPTX 452.0K
- UEIC 63.0K
- Earning Date
- LPTX 11-13-2024
- UEIC 11-07-2024
- Dividend Yield
- LPTX N/A
- UEIC N/A
- EPS Growth
- LPTX N/A
- UEIC N/A
- EPS
- LPTX N/A
- UEIC N/A
- Revenue
- LPTX N/A
- UEIC $382,019,000.00
- Revenue This Year
- LPTX N/A
- UEIC N/A
- Revenue Next Year
- LPTX N/A
- UEIC $6.86
- P/E Ratio
- LPTX N/A
- UEIC N/A
- Revenue Growth
- LPTX N/A
- UEIC N/A
- 52 Week Low
- LPTX $1.55
- UEIC $7.17
- 52 Week High
- LPTX $5.00
- UEIC $14.20
- Technical
- Relative Strength Index (RSI)
- LPTX 39.77
- UEIC 70.98
- Support Level
- LPTX $3.40
- UEIC $10.44
- Resistance Level
- LPTX $3.61
- UEIC $11.71
- Average True Range (ATR)
- LPTX 0.40
- UEIC 0.48
- MACD
- LPTX -0.13
- UEIC 0.28
- Stochastic Oscillator
- LPTX 1.91
- UEIC 79.23
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About UEIC Universal Electronics Inc.
Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.